95
Views
18
CrossRef citations to date
0
Altmetric
Original Research

Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis

, , , , &
Pages 781-792 | Published online: 05 Mar 2018

Figures & data

Table 1 Patient characteristics at baseline

Figure 1 Cohort selection from THIN database of 8,676,730 patient records.

Note: a% of COPD diagnosis cohort.
Abbreviations: FDC, fixed-dose combination; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; THIN, The UK Health Improvement Network.
Figure 1 Cohort selection from THIN database of 8,676,730 patient records.

Table 2 Comorbidities recorded at any time during the study period

Figure 2 Cumulative time to treatment escalation.

Note: a% of all patients (n=14,866).
Figure 2 Cumulative time to treatment escalation.

Table 3 Univariate Cox regression analysis with significant (P<0.05) unadjusted predictors of treatment escalation

Table 4 Multivariate analysis outcomes: predictors of treatment escalation

Table 5 Treatment escalation per GOLD 2011/2013 and 2017 classification

Figure 3 MRC breathlessness score in the treatment-escalation group.

Notes: (A) 12 Months from baseline (n=2,659) and (B) during the study and follow-up period (n=5,611). Median MRC scores at baseline were 2 and 3 during the study period.
Abbreviation: MRC, Medical Research Council.
Figure 3 MRC breathlessness score in the treatment-escalation group.

Table S1 Covariates during the analyzed baseline period